Influenza della sfogliatura sulla sintesi della quercetina in Sangiovese. Ulteriori acquisizioni sui precipitati di quercetina nei vini von Marchi, D., Lanati, D., Cascio, P., Giacomo, M.

Volltext

Composizione in antociani e flavonoli di vini prodotti nel territorio svizzero von Marchi, D., Lanati, D., Mazza, G., Cascio, P.

Volltext

Chiffres privés, chiffres publics xviie-xxie siècle: Entre hybridations et conflits von Cardoni, Fabien, Conchon, Anne, Margairaz, Michel, Touchelay, Béatrice

Volltext

X-linked hypophosphatemic rickets: an Italian experts' opinion survey von Emma, F, Cappa, M, Antoniazzi, F, Bianchi, M L, Chiodini, I, Eller Vainicher, C, Di Iorgi, N, Maghnie, M, Cassio, A, Balsamo, A, Baronio, F, de Sanctis, L, Tessaris, D, Baroncelli, G I, Mora, S, Brandi, M L, Weber, G, D'Ausilio, A, Lanati, E P

Volltext

RWD72 Status of the Art on Global Clinical Trials of Patient-Managed Digital Medical Devices (pDMD): 2023 Original Data Analysis From Multiple Sources von Pagella, V., Lidonnici, D., Lanati, E.P., Rocco, P., Minghetti, P.

Volltext

Concentration experiments of grape musts by reverse osmosis: analytical and organoleptic results of the musts and wines obtained in the 1988 and 1989 vintages von Delfini, C. (Istituto Sperimentale per l'Enologia, Asti (Italy)), Giacosa, D, Nicolini, G, Bardi, L, Lanati, D, Pagliara, A, Borsa, D, Garcia Moruno, E

Volltext

PMU49 NEGOTIATION OUTCOMES IN ITALY: WHAT’S THE IMPACT OF ORPHAN DRUG DESIGNATION? von Enrici, A., Lidonnici, D., Lanati, E.

Volltext

PMU48 P&R PROCESS IN ITALY: A FOCUS ON NEGOTIATION OUTCOMES OF INNOVATIVE DRUGS von Enrici, A., Lidonnici, D., Lanati, E.

Volltext

Out-of-hospital cardiac arrest in COVID-19 era. A single center experience von Aschieri, D, Villani, M, Lanati, M, Didio, M.T, Pellizzoni, V, Villani, G.Q

Volltext

PMH36 - Economic Evaluation of Agomelatine for Major Depressive Disorders Relative to other Antidepressants in the Italian Setting von Lanati, E.P., Lidonnici, D.

Volltext

Economic Evaluation of Agomelatine for Major Depressive Disorders Relative to other Antidepressants in the Italian Setting von Lanati, E.P, Lidonnici, D

Volltext

Proton Pump Inhibitors In Italy: It’s Time to Make A (Policy) Change von Lidonnici, D, Lanati, EP

Volltext

PMU47 ORPHAN DRUG DESIGNATION: NO IMPACT ON P&R PROCESS TIMING IN ITALY von Enrici, A., Lidonnici, D., Isernia, M., Lanati, E.

Volltext

PMU46 POSITIVE IMPACT OF INNOVATIVE STATUS IN P&R PROCESS TIMING IN ITALY von Enrici, A., Lidonnici, D., Isernia, M., Lanati, E.

Volltext

PMU44 FIFTY SHADES OF... INNOVATIVENESS IN ITALY von Casilli, G., Ronco, V., Lidonnici, D., Lanati, E.

Volltext

PMU45 PREVALENCE VS. TREATMENT COST: ANALYSIS OF DRUGS FOR RARE DISEASE IN ITALY von Casilli, G., Lidonnici, D., Morichi, M., Isernia, M., Lanati, E.

Volltext

P208 PREVALENCE OF TRANSTHYRETIN CARDIAC AMYLOIDOSIS IN PATIENTS HOSPITALIZED FOR HEART FAILURE von Lanati, G, Aschieri, D, Di Dio, M, Calabrò, D, Mori, M, Piepoli, M, Rusticali, G

Volltext

ACUTE PERICARDITIS IN A PATIENT WITH PRIMARY HEART LYMPHOMA von Lanati, G, Di Spigno, F, Caraffini, A, Sabatino, M, Covini, D, Turchio, P, Rusticali, G, Febo, O, Aschieri, D

Volltext

PHP76 - ANALYSIS OF APPROVAL TIMING FOR 89 NEW DRUGS IN ITALY FROM JANUARY 2015 TO MAY 2018 von Lidonnici, D., Lanati, E.P., Niedecker, S., Isernia, M.

Volltext

AC1 - OUTCOME OF NEW DRUG NEGOTIATION PROCESS IN ITALY: APPROVAL CONDITIONS (2015-2018) von Lidonnici, D., Lanati, E.P., Niedecker, S., Isernia, M., Ronco, V.

Volltext